GlassScriptPhysician profile
Clara Goodman
NPI 1003589383
$2,258.28
in general payments reported to CMS, 2019-2025
23 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $540 · 2023: $310 · 2024: $380 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $368.68 | 2022 | |
| Abbvie INC. | $247.69 | 2025 | |
| Medtronic, INC. | $231.68 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $162.59 | 2025 | Airsupra, Breztri |
| Pfizer INC. | $141.61 | 2024-2025 | |
| Vertos Medical, INC. | $141.33 | 2023 | Mild Device Kit |
| Boston Scientific Corporation | $138.78 | 2023 | Watchman Flx |
| Lilly USA, LLC | $132.29 | 2022-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $99.87 | 2025 | Veozah |
| Organon LLC | $86.72 | 2022 | |
| Novo Nordisk INC | $85.95 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $54.22 | 2022-2025 | Freestyle Libre 3, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.06 | 2024-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $46.53 | 2025 | Inspire |
| Exact Sciences Corporation | $45.34 | 2023-2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $44.26 | 2024-2025 | Aptima |
| Impulse Dynamics (USA) INC. | $37.08 | 2022-2024 | Optimizer |
| Mayne Pharma Commercial LLC | $33.24 | 2025 | |
| Springworks Therapeutics, INC. | $26.30 | 2025 | Gomekli |
| Organogenesis INC. | $26.26 | 2025 | Apligraf |
| Phathom Pharmaceuticals, INC. | $25.28 | 2025 | Voquezna |
| Amgen INC. | $15.48 | 2025 | Repatha, Otezla |
| Exeltis, USA INC. | $14.04 | 2025 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.